Responses
Regular Abstracts – Part 2
Clinical Trial In Progress
782-D Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity
Compose a Response to This Article
Other responses
No responses have been published for this article.
